A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In two of three phase 3 trials, pirfenidone, an oral antifibrotic therapy, reduced disease progression, as measured by the decline in forced vital capacity (FVC) or vital capacity, in patients with idiopathic pulmonary fibrosis; in the third trial, this end point was not achieved. We sought to confirm the beneficial effect of pirfenidone on disease progression in such patients. METHODS: In this phase 3 study, we randomly assigned 555 patients with idiopathic pulmonary fibrosis to receive either oral pirfenidone (2403 mg per day) or placebo for 52 weeks. The primary end point was the change in FVC or death at week 52. Secondary end points were the 6-minute walk distance, progression-free survival, dyspnea, and death from any cause or from idiopathic pulmonary fibrosis. RESULTS: In the pirfenidone group, as compared with the placebo group, there was a relative reduction of 47.9% in the proportion of patients who had an absolute decline of 10 percentage points or more in the percentage of the predicted FVC or who died; there was also a relative increase of 132.5% in the proportion of patients with no decline in FVC (P<0.001). Pirfenidone reduced the decline in the 6-minute walk distance (P=0.04) and improved progression-free survival (P<0.001). There was no significant between-group difference in dyspnea scores (P=0.16) or in rates of death from any cause (P=0.10) or from idiopathic pulmonary fibrosis (P=0.23). However, in a prespecified pooled analysis incorporating results from two previous phase 3 trials, the between-group difference favoring pirfenidone was significant for death from any cause (P=0.01) and from idiopathic pulmonary fibrosis (P=0.006). Gastrointestinal and skin-related adverse events were more common in the pirfenidone group than in the placebo group but rarely led to treatment discontinuation. CONCLUSIONS: Pirfenidone, as compared with placebo, reduced disease progression, as reflected by lung function, exercise tolerance, and progression-free survival, in patients with idiopathic pulmonary fibrosis. Treatment was associated with an acceptable side-effect profile and fewer deaths. (Funded by InterMune; ASCEND ClinicalTrials.gov number, NCT01366209.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Idiopathic pulmonary fibrosis (IPF), the prototype of fibrotic ILDs, carries a prognosis of 3–5 years survival after diagnosis when untreated. Two anti-fibrotic medications (nintedanib and pirfenidone) have been shown to reduce the rate of forced vital capacity (FVC) decline and slow disease progression in patients with a definite usual interstitial pneumonia (UIP) pattern and with a probable UIP pattern on high resolution CT (HRCT).(191–193)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [191]
In the citing paper
“However, both have significant adverse effects and neither completely arrest the decline in lung function.”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [13]
In the citing paper
“In three trials with doses that reached 2403 mg/day, pirfenidone effectively reduced FVC decline although had variable reductions in overall mortality and IPF-related mortality [12,13].”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [13]
In the citing paper
“Reported adverse events in the present trial were generally acceptable and largely consistent with events previously reported by participants in the placebo arms of randomized controlled trials in IPF [45,46].”
From Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study (2019) · cites this paper as [45]
In the citing paper
“FVC is the gold-standard metric for assessing the lung function of patients with IPF and response to therapeutic intervention33–35.”
From A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial (2025) · cites this paper as [35]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationA sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
Noble, P. W., Albera, C., Bradford, W. Z., Costabel, U., Glassberg, M. K., Kardatzke, D., King, T. E., Lancaster, L., Sahn, S. A., Szwarcberg, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60405-4 · Cited by 2,154
Self-citationDouble-blind, Placebo-controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
Azuma, A., Nukiwa, T., Tsuboi, E., Suga, M., Abe, S., Nakata, K., Taguchi, Y., Nagai, S., Itoh, H., Ohi, M., et al. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200404-571oc · Cited by 954
Pirfenidone in idiopathic pulmonary fibrosis
Taniguchi, H., Ebina, M., Kondoh, Y., Ogura, T., Azuma, A., Suga, M., Taguchi, Y., Takahashi, H., Nakata, K., Sato, A., et al. (2010) · European Respiratory Journal · doi:10.1183/09031936.00005209 · Cited by 946
Pirfenidone in idiopathic pulmonary fibrosis: Figure 1–
Swigris, J., & Fairclough, D. (2010) · European Respiratory Journal · doi:10.1183/09031936.00071710 · Cited by 799
Self-citationChanges in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764
Self-citationThe Clinical Course of Patients with Idiopathic Pulmonary Fibrosis
Martinez, F. J., Safrin, S., Weycker, D., Starko, K. M., Bradford, W. Z., King, T. E., Flaherty, K. R., Schwartz, D. A., Noble, P. W., Raghu, G., et al. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-12_part_1-200506210-00005 · Cited by 622
Self-citationKing, T. E., Albera, C., Bradford, W. Z., Costabel, U., Hormel, P., Lancaster, L., Noble, P. W., Sahn, S. A., Szwarcberg, J., Thomeer, M., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60551-1 · Cited by 531
Self-citation
Cited by
Items 2,401–2,500 of 3,965
Effect of pirfenidone protecting against cigarette smoke extract induced apoptosis
Ma, Y., Liu, X., Luo, L., Li, H., Zeng, Z., & Chen, Y. (2022) · Tobacco Induced Diseases · doi:10.18332/tid/146169 · Cited by 6
Coronary artery calcium score is a prognostic factor for mortality in idiopathic pulmonary fibrosis
Caminati, A., Zompatori, M., Fuccillo, N. R. T. D. A., Sonaglioni, A., Elia, D., Cassandro, R., Trevisan, R., Rispoli, A., Pelosi, G., & Harari, S. A. (2022) · Minerva Medica · doi:10.23736/s0026-4806.22.08018-1 · Cited by 8
Wang, F., Zhang, Y., Ren, J. F., & Yu, W. (2022) · Folia Histochemica et Cytobiologica · doi:10.5603/fhc.a2022.0022 · Cited by 7
Salonen, J., Purokivi, M., Hodgson, U., & Kaarteenaho, R. L. (2022) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2022-001363 · Cited by 12
Li, H., Yang, J., Chen, S., Wang, P., Yu, X., Zhou, Q., Zhang, X., & Zhang, G. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1055702 · Cited by 9
“The Food and Drug Association (FDA) has approved the antifibrotic drugs pirfenidone (Noble et al., 2011; King et al., 2014) and nintedanib (Richeldi et al.”
BackgroundYagasaki, H., Takekoshi, S., Kitatani, K., Kato, C., Yamasaki, H., Shioyama, K., Tsuboi, T., Matsuzaki, T., Inagaki, Y., Masuda, R., et al. (2022) · Free Radical Research · doi:10.1080/10715762.2022.2092477 · Cited by 7
Chikina, S. Y., Cherniak, A. V., Мержоева, З. М., Tyurin, I. E., Трушенко, Н. В., Proshkina, A. A., Ataman, K. S., & Avdeev, S. N. (2023) · Life · doi:10.3390/life13020435 · Cited by 7
Topological data analysis identifies molecular phenotypes of idiopathic pulmonary fibrosis
Shapanis, A. G., Jones, M. G., Schofield, J. P. R., & Skipp, P. J. S. (2023) · Thorax · doi:10.1136/thorax-2022-219731 · Cited by 7
Anti-fibrotic strategies and pulmonary fibrosis
Gunatilaka, A., Zhang, S., Tan, W. S. D., & Stewart, A. G. (2023) · Advances in pharmacology · doi:10.1016/bs.apha.2023.04.002 · Cited by 7
Nailfold capillaroscopy findings of interstitial pneumonia with autoimmune features
Lee, S., Min, H. K., Kim, S., Kim, Y. W., Yoo, K. H., Kim, H. J., Kim, I. A., & Kim, H. (2023) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2022.358 · Cited by 8
Jastrzębski, D., Kostorz‐Nosal, S., Galle, D., et al. (2023) · Health Science Reports · doi:10.1002/hsr2.1449 · Cited by 6
Gao, Y., Yang, Z., He, K., Wang, Z., Zhang, T., Jiang, Y., & Zhao, L. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.122066 · Cited by 6
Moncomble, E., Weisenburger, G., Picard, C., Dégot, T., Reynaud‐Gaubert, M., Nieves, A., Mornex, J., Dauriat, G., Messika, J., Godet, C., et al. (2023) · Respirology · doi:10.1111/resp.14605 · Cited by 7
Diagnostic Approaches for Idiopathic Pulmonary Fibrosis
Lee, J. H., & Song, J. W. (2023) · Tuberculosis & respiratory diseases · doi:10.4046/trd.2023.0087 · Cited by 10
A formula for predicting emphysema extent in combined idiopathic pulmonary fibrosis and emphysema
Wells, A. U., Jacob, J., Sverzellati, N., Cross, G., Barnett, J. L., Lauretis, A. D., Antoniou, K. M., Weycker, D. A., Atwood, M., Kirchgaessler, K.-U., et al. (2024) · Respiratory Research · doi:10.1186/s12931-023-02589-x · Cited by 6
Brg1/PRMT5 nuclear complex epigenetically regulates FOXO1 in IPF mesenchymal progenitor cells
Jbeli, A. H., Yang, L., Hong, X., et al. (2024) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00248.2023 · Cited by 6
Lee, K. S., Yeom, S. H., Kim, M. K., Woo, C. H., Choi, Y. C., Choi, J. S., & Cho, Y. W. (2024) · Extracellular Vesicle · doi:10.1016/j.vesic.2024.100045 · Cited by 7
Mathai, S. K., & Schwartz, D. A. (2015) · European Respiratory Journal · doi:10.1183/09031936.00052715 · Cited by 7
Parenchymal cryobiopsies for interstitial lung diseases: A step forward in disease management
Maldonado, F., Moua, T., & Skalski, J. H. (2014) · Respirology · doi:10.1111/resp.12332 · Cited by 6
Idiopathic pulmonary fibrosis: moving forward
Richeldi, L. (2015) · BMC Medicine · doi:10.1186/s12916-015-0481-6 · Cited by 6
Cutaneous reactions to pirfenidone: a new kid on the block
Caruana, D. M., & Wylie, G. (2016) · British Journal of Dermatology · doi:10.1111/bjd.14555 · Cited by 6
Kristof, A. S., Petrof, B. J., Hamid, Q. A., Kolb, M. R. J., Landry, J., MacKenzie, A., McCormack, F. X., Murawski, I. J., Moss, J., Rauch, F., et al. (2017) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201705-406ws · Cited by 7
Undifferentiated Pleomorphic Sarcoma after Pirfenidone Use: A Case Report
Moore, C. A., & Kapila, A. (2018) · The Permanente Journal · doi:10.7812/tpp/17-116 · Cited by 6
Davis, S., Rafia, R., Carroll, C., Hamilton, J., & Essat, M. (2018) · PharmacoEconomics · doi:10.1007/s40273-018-0727-1 · Cited by 6
Another Weapon in the Battle against Idiopathic Pulmonary Fibrosis?
Wilson, C. L., & Hung, C. F. (2019) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2018-0387ed · Cited by 6
Parametric Time‐to‐Event Model for Acute Exacerbations in Idiopathic Pulmonary Fibrosis
Tang, F., Weber, B., Stowasser, S., & Korell, J. (2020) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12485 · Cited by 6
Higo, H., Miyahara, N., Taniguchi, A., Senoo, S., Itano, J., Watanabe, H., Oda, N., Kayatani, H., Ichikawa, H., Shibayama, T., et al. (2020) · Respiratory Investigation · doi:10.1016/j.resinv.2019.12.007 · Cited by 9
Sokai, A., Handa, T., Oga, T., Tanizawa, K., Ikezoe, K., Nakatsuka, Y., Kubo, T., Kumiko, K., Chin, K., & Mishima, M. (2017) · Sarcoidosis vasculitis and diffuse lung diseases · doi:10.36141/svdld.v34i3.5214 · Cited by 9
Wells, A. U., & Kouranos, V. (2021) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2021.1968832 · Cited by 6
Zhang, D., Zhuang, R., Li, J., Lv, Y., Yang, X., Pan, W., & Zhang, X. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.1c00545 · Cited by 6
Antifibrotic Therapy for Idiopathic Pulmonary Fibrosis
Khor, Y. H. (2021) · CHEST Journal · doi:10.1016/j.chest.2021.07.033 · Cited by 7
Klay, D., van der Vis, J. J., Roothaan, S. M., Nguyen, T. Q., Grutters, J. C., Goldschmeding, R., & van Moorsel, C. H. M. (2021) · Lung · doi:10.1007/s00408-021-00494-y · Cited by 7
Wang, J., Zhao, X., Feng, W., Li, Y., & Peng, C. Y. (2021) · The American Journal of Chinese Medicine · doi:10.1142/s0192415x21500932 · Cited by 6
Nintedanib in the management of pulmonary fibrosis after COVID-19: a case report
Chakrabortty, R., Rahman, S., Jahan, R., Dip, A. H., & Rahman, M. M. (2021) · BIRDEM Medical Journal · doi:10.3329/birdem.v11i2.53139 · Cited by 6
Schnitzler, M. A., Valapour, M., Skeans, M. A., et al. (2016) · American Journal of Transplantation · doi:10.1111/ajt.13672 · Cited by 6
Immunity, Ciliated Epithelium, and Mortality
Juan-Guardela, B. M., & Herazo‐Maya, J. D. (2022) · CHEST Journal · doi:10.1016/j.chest.2022.02.018 · Cited by 6
Synthesis and evaluation of new pirfenidone derivatives as anti-fibrosis agents
Gu, C., Li, W., Ju, Q., Yao, H., Yang, L., An, B., Hu, W., & Li, X. (2022) · RSC Advances · doi:10.1039/d2ra00990k · Cited by 7
Fikry, H., Saleh, L. A., & Gawad, S. A. (2022) · PubMed · doi:10.14670/hh-18-493 · Cited by 8
Pulmonary Hypertension in Scleroderma– Evaluation and Management
Chennakesavulu, P. V., Uppaluri, S., Koyi, J., Jhaveri, S., Avanthika, C., Sakhamuri, L. T., Ashokbhai, P. K., & Singh, P. (2022) · Disease-a-Month · doi:10.1016/j.disamonth.2022.101468 · Cited by 7
Content Analysis of Idiopathic Pulmonary Fibrosis-Related Information on Twitter
Ong, S., Koo, J., Johannson, K. A., Ryerson, C. J., & Goobie, G. C. (2022) · ATS Scholar · doi:10.34197/ats-scholar.2022-0054oc · Cited by 6
The Syndrome of Combined Pulmonary Fibrosis and Emphysema
Cottin, V. (2023) · Springer eBooks · doi:10.1007/978-3-031-12950-6_33 · Cited by 6
Kass, D. J., Flynn, M., & Baker, E. (2015) · Current Biomarker Findings · doi:10.2147/cbf.s81362 · Cited by 7
Key, A. L., Holt, K. J., Warburton, C. J., Walker, P. P., & Earis, J. E. (2018) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2017-135320 · Cited by 7
P311 in Scar Wars: Myofibroblasts Lost without Transforming Growth Factor β Translation
Lagares, D. (2018) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2018-0255ed · Cited by 6
Clinical importance of Bcl-2-like 11 deletion polymorphism in idiopathic pulmonary fibrosis
Isobe, K., Issiki, T., Sakamoto, S., Sano, G., Takai, Y., Tochigi, N., & Homma, S. A. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2019.07.25 · Cited by 5
Three Steps to Cure Pulmonary Fibrosis. Step 1: The Runaway Train or Groundhog Day?
Jenkins, G. R. (2020) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202002-0260ed · Cited by 6
Disease progression across the spectrum of idiopathic pulmonary fibrosis: A multicentre study
Sgalla, G., Greco, E. L., Calvello, M., Varone, F., Iovene, B., Cerri, S., Donatelli, P., Vancheri, A., Pavone, M., Luppi, F., et al. (2020) · Respirology · doi:10.1111/resp.13805 · Cited by 7
Opportunities to diagnose fibrotic lung diseases in routine care: A primary care cohort study
Jones, M. G., Hillyar, C., Nibber, A., Chisholm, A., Wilson, A. M., Maher, T. M., Kaplan, A. G., Price, D. B., Walsh, S. L. F., Richeldi, L., et al. (2020) · Respirology · doi:10.1111/resp.13836 · Cited by 6
“Anthropomorphic and lung function measures are consistent with previous IPF cohorts [6,8,9,21].”
BackgroundResultPang, Q., Li, G., Cao, F., Liu, H., Wei, W., & Jiao, Y. (2022) · PLoS ONE · doi:10.1371/journal.pone.0265006 · Cited by 8
Update in Interstitial Lung Disease 2016
Wells, A. U., & Maher, T. M. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201702-0351up · Cited by 8
Broad Adoption of Antifibrotics in Idiopathic Pulmonary Fibrosis: Still a Long Way to Go
Assayag, D. (2021) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202102-123ed · Cited by 6
Dubey, S., & Woodhead, F. (2023) · Rheumatology International · doi:10.1007/s00296-023-05505-0 · Cited by 6
Current perspectives on interstitial lung abnormalities
Oh, J. H., & Song, J. W. (2025) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2024.335 · Cited by 6
Kim, G. H. J., Zhang, X., Brown, M. S., Poole, L., & Goldin, J. G. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-094559 · Cited by 8
Global trends in idiopathic pulmonary fibrosis mortality rates during 2001–2022
Harada, K., Nishimura, Y., Vu, Q. T., Yamamoto, M., Koyama, T., & Hagiya, H. (2025) · ERJ Open Research · doi:10.1183/23120541.00362-2025 · Cited by 9
Yang, Y., Huang, G., Zhang, T., Ling, Y., Jiang, J., Du, D., Ma, Y., & Tao, S. (2025) · Advanced Science · doi:10.1002/advs.202501718 · Cited by 8
Yang, Z. R., Ji, P., Zhang, W., Li, C., Wu, F., Hua, Y., Wei, Y., & Cao, Y. (2025) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2025.120384 · Cited by 5
Belmans, F., Persson, I. M., Bayat, S., Eaden, J. A., Vos, W. G., Jacob, J., Chambers, R. C., & Velde, G. V. (2025) · European Respiratory Review · doi:10.1183/16000617.0012-2025 · Cited by 7
Matson, S. M., Ngo, L. T., Sugawara, Y., Fernando, V., Lugo, C., Kaczorowski-Worthley, A., Azeem, I., Harrison, A., Alsup, A., Schueddig, E., et al. (2025) · iScience · doi:10.1016/j.isci.2025.114125 · Cited by 19
Ryerson, C. J., Piciucchi, S., Travis, W. D., Nicholson, A. G., & Adegunsoye, A. (2026) · European Respiratory Journal · doi:10.1183/13993003.02312-2025 · Cited by 11
RP-182 alleviated obstruction-induced renal fibrosis by reprogramming CD206+ macrophages
Cao, H., Chen, X., Jin, R., Yang, Y., Tao, Y., Li, P., Wu, Y., Chen, G., Zhao, J., Wen, J., et al. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1739457 · Cited by 9
“Pirfenidone, a broad-spectrum antifibrotic agent, acts by modulating TGF-β signaling, reducing inflammation, and scavenging reactive oxygen species, showing clinical benefit in idiopathic pulmonary fibrosis (King et al., 2014).”
Clinical Impact of Surgical Lung Biopsy for Interstitial Lung Disease in a Reference Center
Guen, P. L., Iquille, J., Debray, M., Guyard, A., Roussel, A., Borie, R., Dombret, M.-C., Dupin, C., Ghanem, M., Taillé, C., et al. (2021) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2021.07.038 · Cited by 6
Singer, D., Chastek, B. J., Sargent, A., Johnson, J., Shetty, S. S., Conoscenti, C., & Bernstein, E. J. (2023) · BMC Pulmonary Medicine · doi:10.1186/s12890-023-02637-8 · Cited by 6
Swigris, J. J., Danoff, S. K., Dellaripa, P. F., Doyle, T. J., & Solomon, J. J. (2023) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2023-001872 · Cited by 5
Self-citationThrainsson, L., Halldórsson, A. B., Ingason, A. B., Ísaksson, H. J., Gudmundsson, G., & Guðbjartsson, T. (2024) · Journal of Thoracic Disease · doi:10.21037/jtd-23-1107 · Cited by 7
Cassel, S. E., Huntington, B. M., Chen, W., Lei, P., Andreadis, S. T., & Kloxin, A. M. (2024) · APL Bioengineering · doi:10.1063/5.0166152 · Cited by 6
Assessment of Imatinib Anti-Remodeling Activity on a Human Precision Cut Lung Slices Model
Bozzinì, S., Bozza, E., Bagnera, C., Morbini, P., Lettieri, S., Zoppa, M. D., Melloni, G., Saracino, L., Belliato, M., & Meloni, F. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25158186 · Cited by 5
Dissecting the lung transcriptome of pulmonary fibrosis-associated pulmonary hypertension
Brownstein, A. J., Mura, M., Ruffenach, G., Channick, R. N., Saggar, R., Kim, A., Umar, S., Eghbali, M., Yang, X., & Hong, J. S. (2024) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00166.2024 · Cited by 6
Behr, J., Bonella, F., Frye, B. C., Günther, A., Hagmeyer, L., Henes, J., Klemm, P., Koschel, D., Kreuter, M., Leuschner, G., et al. (2024) · Respiration · doi:10.1159/000540856 · Cited by 13
Kulkarni, T., Flaherty, K. R., Gupta, S., Tu, Y.-H., & Case, A. H. (2024) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202404-430rl · Cited by 7
Balakrishnan, B., AZAR, J. J., Farha, S., Goyanes, A. M., Lane, J. E., Paul, D., Highland, K. B., Wang, Y., Wang, X., & Tonelli, A. R. (2024) · Respiratory Medicine · doi:10.1016/j.rmed.2024.107835 · Cited by 6
Wang, F., Jin, L., Wang, X., Cui, B., Yang, Y., Duggan, L., Sterman, A. S., Lloyd, S. M., Hazelwood, L. A., Chaudhary, N., et al. (2025) · Proteomes · doi:10.3390/proteomes13010003 · Cited by 9
Inhalable Hsa‐miR‐30a‐3p Liposomes Attenuate Pulmonary Fibrosis
Liu, S., Popowski, K. D., Eckhardt, C. M., Zhang, W., Li, J., Jing, Y., Silkstone, D., Belcher, E., Cislo, M., Hu, S., et al. (2025) · Advanced Science · doi:10.1002/advs.202405434 · Cited by 15
Mechanism study of the effects of astragaloside IV and quercetin on idiopathic pulmonary fibrosis
Luo, Y., Xu, C.-J., Ai, X., et al. (2025) · Journal of Natural Medicines · doi:10.1007/s11418-025-01896-5 · Cited by 5
Algal bioactives: Unlocking future frontiers in respiratory therapeutics
Pakan, P. D., Siu, A. C. W., Lee, H., Singh, M., Rubis, G. D., Yeung, S., Kulkarni, M. P., Goh, B. H., Hsu, A., Chellappan, D. K., et al. (2025) · Food Bioscience · doi:10.1016/j.fbio.2025.106778 · Cited by 8
A safety evaluation of pirfenidone for the treatment of idiopathic pulmonary fibrosis
Anderson, A., Shifren, A., & Nathan, S. D. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2016.1187129 · Cited by 5
Self-citationStudy on Perioperative Administration of a Neutrophil Elastase Inhibitor for Interstitial Pneumonias
Fukui, M., Takamochi, K., Oh, S., Matsunaga, T., Suzuki, K., Ando, K., & Suzuki, K. (2017) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2016.12.022 · Cited by 7
Pulmonary fibrosis in connective tissue disease (CTD): urgent challenges and opportunities
Fischer, A., & Donnelly, S. C. (2017) · QJM · doi:10.1093/qjmed/hcx140 · Cited by 5
Acupuncture for idiopathic pulmonary fibrosis
Xie, Y., Wang, J., Li, G., et al. (2017) · Medicine · doi:10.1097/md.0000000000009114 · Cited by 5
Systemic sclerosis phase III clinical trials: Hope on the horizon?
Aringer, M., & Denton, C. P. (2018) · Journal of Scleroderma and Related Disorders · doi:10.1177/2397198318775353 · Cited by 6
Was der Rheumatologe vom Pneumologen lernen kann
Leuschner, G., & Neurohr, C. (2018) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-018-0507-5 · Cited by 6
Pharmacological treatment of pulmonary fibrosis
Choi, W.-I. (2020) · Journal of Korean Medical Association · doi:10.5124/jkma.2020.63.1.47 · Cited by 5
Early referral to palliative care in IPF – pitfalls and opportunities in clinical trials
Kalluri, M., Bendstrup, E. M., Lindell, K. O., et al. (2020) · Respiratory Research · doi:10.1186/s12931-020-01418-9 · Cited by 5
Infections and systemic sclerosis: an emerging challenge
Correa, J. E. B., la Hoz, A. D., López, M. J., Garzón, J., Allanore, Y., & Quintana‐López, G. (2020) · Revista Colombiana de Reumatología (English Edition) · doi:10.1016/j.rcreue.2019.12.004 · Cited by 8
Legué, S., Marchand-Adam, S., Plantier, L., Bayeh, B. A., Morel, H., Mangiapan, G., & Flament, T. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-039078 · Cited by 5
Davis, R., Dixon, C., Millar, A., Maskell, N. A., & Barratt, S. L. (2021) · BMC Pulmonary Medicine · doi:10.1186/s12890-021-01520-8 · Cited by 7
Kim, M., & Park, S. (2021) · Heart Failure Clinics · doi:10.1016/j.hfc.2021.02.008 · Cited by 6
Anti-fibrotic Treatment for Pulmonary Fibrosis Induced by COVID-19: A Case Presentation
UYAR, B. S., Ensarıoğlu, K., Kurt, B., Özkan, D., & Güneş, S. Ö. (2021) · Türk anesteziyoloji ve reanimasyon derneği dergisi · doi:10.5152/tjar.2021.20450 · Cited by 5
Xiao-ling, Z., Yuan, S., Zheng, X., Wang, X., & Zhang, J. (2022) · Inflammation · doi:10.1007/s10753-022-01653-w · Cited by 6
Zheng, Q., Cox, I. A., de Graaff, B., Campbell, J. A., Corte, T. J., Glaspole, I., Navaratnam, V. V., Hopkins, P. M.-A., Zappala, C. J., Ahmad, H., et al. (2022) · Quality of Life Research · doi:10.1007/s11136-022-03331-8 · Cited by 5
Self-citationAntifibrotic in interstitial lung diseases: When, where, and how long?
Rai, D. K., & Tripathi, S. (2022) · Lung India · doi:10.4103/lungindia.lungindia_283_22 · Cited by 5
Sviridenko, A., di Santo, G., & Virgolini, I. J. (2023) · PET Clinics · doi:10.1016/j.cpet.2023.02.004 · Cited by 5
Rodríguez‐Nieto, M. J., Cano-Jiménez, E., Ortíz, A. D. R., Villar, A., Morros, M., Ramón, A., & Armengol, S. (2023) · PharmacoEconomics · doi:10.1007/s40273-023-01278-3 · Cited by 7
Hosokawa, M., Mikawa, R., Hagiwara, A., Okuno, Y., Awaya, T., Yamamoto, Y., Takahashi, S., Yamaki, H., Osawa, M., Setoguchi, Y., et al. (2023) · iScience · doi:10.1016/j.isci.2023.107731 · Cited by 7
Kaunisto, J., Salomaa, E.-R. M., Koivisto, M. A., & Myllärniemi, M. (2023) · BMC Pulmonary Medicine · doi:10.1186/s12890-023-02630-1 · Cited by 10
Jo, Y. S., Kim, K., Rhee, C. K., & Kim, Y. H. (2023) · Scientific Reports · doi:10.1038/s41598-023-46506-0 · Cited by 5
Wang, Z., Liu, M., Ai, Y., Zheng, S., Chen, Y., Du, H., Yuan, S., Guo, X., Yuan, Y., Li, G., et al. (2023) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2023.102268 · Cited by 5
Ukita, J., Nishikiori, H., Hirota, K., et al. (2024) · BMJ Open · doi:10.1136/bmjopen-2023-078841 · Cited by 5
Takuma, S., Suzuki, Y., Kono, M., Hasegawa, H., Hashimoto, D., Yokomura, K., Mori, K., Shimizu, M., Inoue, Y., Yasui, H., et al. (2024) · Respiratory Medicine · doi:10.1016/j.rmed.2024.107542 · Cited by 4
Zamparelli, S. S., Lombardi, C., Candia, C., Iovine, P. R., Rea, G., Vitacca, M., Ambrosino, P., Bocchino, M., & Maniscalco, M. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13072026 · Cited by 14
“…and nintedanib are the only two approved and commercially available antifibrotic drugs (AFDs); their actions result in a significant slowdown of the disease’s progression [5,6], but the prognosis remains unsatisfactorily poor, and the burden of the disease is still unbearable for most patients.”
Background
Metadata
- Authors
- King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., Lederer, D. J., Nathan, S. D., Pereira, C. A., Sahn, S. A., Sussman, R., Swigris, J. J., & Noble, P. W.
- Affiliations
- Cedars-Sinai Medical Center (US)
- The Alfred Hospital (AU)
- University of Miami (US)
- Prince Charles Hospital (AU)
- Vanderbilt University Medical Center (US)
- Columbia University Irving Medical Center (US)
- Inova Fairfax Hospital (US)
- Universidade Federal de São Paulo (BR)
- Medical University of South Carolina (US)
- Overlook Medical Center (US)
- National Jewish Health (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-05-29
- Volume
- 370
- Issue
- 22
- Pages
- 2083-2092
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2168666423
- Cited by
- 3,975
- References
- 27
- Citations by year
- 2026: 272 · 2025: 303 · 2024: 371 · 2023: 315 · 2022: 339 · 2021: 412 · 2020: 343 · 2019: 310 · 2018: 335 · 2017: 319 · 2016: 288 · 2015: 279 · 2014: 76
- FWCI
- 256.80
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UNIFESP Institutional Repository (Universidade Federal de São Paulo) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- pirfenidone, idiopathic pulmonary fibrosis, antifibrotic therapy, forced vital capacity decline, disease progression, mortality, progression-free survival, 6-minute walk distance, dyspnea, gastrointestinal adverse effects, cutaneous adverse events, exercise tolerance, lung function decline, safety and tolerability
- MeSH terms
- Administration, Oral, Adult, Aged, Aged, 80 and over, Antifibrinolytic Agents, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Male, Middle Aged, Pyridones, Vital Capacity, Treatment Outcome, Disease Progression, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.